Anavex Life Sciences Corp. (AVXL)

3.13
0.01 0.16
NASDAQ
Prev Close 3.14
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.91 / 14.84
Exchange NASDAQ
Shares Outstanding 35.71B
Market Cap 113.56M
Div & Yield N.A. (N.A)

Latest News

Noteworthy Wednesday Option Activity: AVXL, CRUS, ASPS

Noteworthy Wednesday Option Activity: AVXL, CRUS, ASPS

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Anavex Life Sciences Corp , where a total volume of 10,707 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 90.4% of AVXL's average daily trading volume over the past month, of 1.2 million shares.

Anavex Alzheimer's Drug Plays Losing Game Against Placebo Effect

Anavex Alzheimer's Drug Plays Losing Game Against Placebo Effect

A small group of Alzheimer's patients treated with Anavex 2-73 are exhibiting signs of memory loss, faltering cognition and inability to take care of themselves over time.

Notable Friday Option Activity: AVXL, WNR, RLYP

Notable Friday Option Activity: AVXL, WNR, RLYP

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Anavex Life Sciences Corp , where a total of 3,227 contracts have traded so far, representing approximately 322,700 underlying shares. That amounts to about 41.6% of AVXL's average daily trading volume over the past month of 776,365 shares.

These 5 Stocks Are Ready to Break Out Now

These 5 Stocks Are Ready to Break Out Now

These stocks look ready to break out and trade higher from current levels.

Anavex Announces Positive Preclinical Results With ANAVEX 2-73 In Fragile X - Autism-Related Disorders

Anavex Announces Positive Preclinical Results With ANAVEX 2-73 In Fragile X - Autism-Related Disorders

Shared clinical phenotypes and underlying pathophysiology of Autism-Related Disorders such as Fragile X and Rett syndrome, indicates that ANAVEX 2-73 could be of interest to investigate clinically in these disorders

Anavex Announces Positive Preclinical Data For ANAVEX 2-73 In Infantile Spasms

Anavex Announces Positive Preclinical Data For ANAVEX 2-73 In Infantile Spasms

Detailed Data to be Presented at Upcoming Scientific Meeting

Anavex Plays the Orphan Drug Stock Promotion Game

Anavex Plays the Orphan Drug Stock Promotion Game

Too many investors have a fundamental misunderstanding about the significance of orphan drug designation. I should say, insignificance, because the FDA delineation, on its own, means very little.

Stocks Edge Higher as Crude Surges on Oil Rig Count Decline

Stocks Edge Higher as Crude Surges on Oil Rig Count Decline

Stocks edge higher on Friday afternoon as crude oil continues to race toward the $40 level.

Stocks Climb as Oil Extends Massive Surge

Stocks Climb as Oil Extends Massive Surge

Stocks extend highs on Friday as a surge in crude oil boosts the energy sector.

Here's Why Anavex (AVXL) Stock is Soaring Today

Here's Why Anavex (AVXL) Stock is Soaring Today

Anavex (AVXL) stock is surging in mid-morning trading on Friday after the FDA granted the company's dementia treatment with an Orphan Drug Designation.

Stock Futures Set for Bounce in Whiplash End to Week

Stock Futures Set for Bounce in Whiplash End to Week

Stock futures set up for a bounce on Friday in a hard left turn to the selloff that punished Wall Street a day earlier.

Anavex Presents New Data On Preclinical Development Of ANAVEX 3-71

Anavex Presents New Data On Preclinical Development Of ANAVEX 3-71

Results Demonstrate Significant Reversal in Cognitive Deficit, Inflammation and Alzheimer's-like Amyloid Pathology

Anavex Announces Two-Year Clinical Extension Study Of ANAVEX 2-73 And Presents Phase 2a Dose-Response Analysis At AAT Conference

Anavex Announces Two-Year Clinical Extension Study Of ANAVEX 2-73 And Presents Phase 2a Dose-Response Analysis At AAT Conference

Trial Extension Granted at Request of Patients and Caregivers

Scott + Scott, LLP Reminds Investors That Monday, Feb. 29, 2016 Is The Last Day To File Lead Plaintiff Papers In The Anavex Life Sciences (AVXL) Securities Case

Scott + Scott, LLP Reminds Investors That Monday, Feb. 29, 2016 Is The Last Day To File Lead Plaintiff Papers In The Anavex Life Sciences (AVXL) Securities Case

Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, February 29, 2016 is the deadline for filing lead plaintiff papers in the securities lawsuit against Anavex Life...

Scott + Scott, LLP Reminds Investors Of Monday, Feb. 29, 2016 Deadline In Anavex Life Sciences (AVXL) Securities Case

Scott + Scott, LLP Reminds Investors Of Monday, Feb. 29, 2016 Deadline In Anavex Life Sciences (AVXL) Securities Case

Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, February 29, 2016 is the deadline for filing lead plaintiff papers in the securities lawsuit against Anavex Life...

Scott + Scott, LLP Reminds Investors Of Deadline To File Lead Plaintiff Papers In Anavex Life Sciences (AVXL) Securities Lawsuit

Scott + Scott, LLP Reminds Investors Of Deadline To File Lead Plaintiff Papers In Anavex Life Sciences (AVXL) Securities Lawsuit

Scott + Scott, LLP, a global investor rights law firm, reminds investors that Monday, February 29, 2016 is the deadline for filing lead plaintiff papers in the securities lawsuit against Anavex Life Sciences (AVXL).

IMPORTANT SHAREHOLDER ALERT: Scott + Scott, LLP Investigating Anavex Life Sciences (AVXL) For Possible Securities Fraud

IMPORTANT SHAREHOLDER ALERT: Scott + Scott, LLP Investigating Anavex Life Sciences (AVXL) For Possible Securities Fraud

Scott + Scott, LLP, a global investor rights law firm, has opened an investigation to determine whether Anavex Life Sciences (AVXL) violated the federal securities laws by issuing materially misleading information to the...

SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Anavex Life Sciences Corp. And Reminds Investors With Losses In Excess Of $250,000 To Contact The Firm

SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Anavex Life Sciences Corp. And Reminds Investors With Losses In Excess Of $250,000 To Contact The Firm

Lundin Law PC announces a class action lawsuit has been filed against Anavex Life Sciences Corp.